(Q43255700)

17 November 2017

title

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study (English)

1 reference

17 November 2017

0 references

1 reference

1 reference

Arne Astrup

1

0 references

Stephan Rössner

2

object named as

Stephan Rössner

1 reference

17 November 2017

9

Michael E J Lean

1 reference

17 November 2017

Luc Van Gaal

3

1 reference

17 November 2017

Aila Rissanen

4

1 reference

17 November 2017

Leo Niskanen

5

1 reference

17 November 2017

Mazin Al Hakim

6

1 reference

17 November 2017

Jesper Madsen

7

1 reference

17 November 2017

Mads F Rasmussen

8

1 reference

17 November 2017

NN8022-1807 Study Group

10

1 reference

17 November 2017

language of work or name

English

0 references

publication date

23 October 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

374

1 reference

17 November 2017

issue

9701

1 reference

17 November 2017

page(s)

1606-1616

1 reference

Obesity prevalence from a European perspective: a systematic review

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

The obesity epidemic, metabolic syndrome and future prevention strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Mechanisms linking obesity with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Obesity and health-related quality of life: a cross-sectional analysis of the US population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Liraglutide Effect and Action in Diabetes (LEAD™) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

The effects of pharmacologic agents for type 2 diabetes mellitus on body weight

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Prescription of diabetic diets in the 1980s.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Development of a brief measure to assess quality of life in obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Follow-up report on the diagnosis of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961375-1

7 January 2021

10.1016/S0140-6736(09)61375-1

Identifiers

DOI

1 reference

17 November 2017

1 reference